EWTX — Edgewise Therapeutics Inc
NASDAQ · Healthcare · Biotechnology
$42.25
+$0.48 (+1.15%)
Edgewise Therapeutics Inc (EWTX) is a biotechnology company listed on NASDAQ. It is led by Kevin Koch Ph.D., based in 1715 38th Street, Boulder, CO, United States, 80301, with about 154 employees. Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, sevasemten, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials; and EDG-15400, a novel small molecule for the treatment of heart failure with preserved ejection fraction. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. The company was incorporated in 2017 and is headquartered in Boulder, Colorado.
Net income was -$117.6M. EWTX currently screens at market cap $3.75B.
Use this EWTX page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the EWTX quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the EWTX SEC filings page. Lician reads the product cache first so this HTML stays unique to Edgewise Therapeutics Inc even when a live quote feed is slow.
About Edgewise Therapeutics Inc
Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, sevasemten, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials; and EDG-15400, a novel small molecule for the treatment of heart failure with preserved ejection fraction. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. The company was incorporated in 2017 and is headquartered in Boulder, Colorado.
EWTX Key Statistics
Market Cap
$3.75B
Volume
530,472
Previous Close
$44.72
Day Range
$44.68 – $46.31
P/B Ratio
7.60
EPS
-$1.45
Revenue
$0.00
Net Income
-$133.81M
Gross Profit
$0.00
Free Cash Flow
$0.00
Employees
154
EWTX Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$133.81M | -$100.16M | -$67.64M | -$42.81M |
| EPS (Diluted) | -$1.45 | -$1.57 | -$1.26 | -$1.14 |
Total Assets
$486.82M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$41.67M
Operating Cash Flow
-$109.03M
Free Cash Flow
$0.00
Edgewise Therapeutics Inc Company Information
- President, CEO & Director
- Kevin Koch Ph.D.
- Headquarters
- 1715 38th Street, Boulder, CO, United States, 80301
- Website
- edgewisetx.com
- Phone
- 720 262 7002
- IPO / Founded
- 2021-03-26
- Sector
- Healthcare
- Industry
- Biotechnology